CALR and neoplasm: In order to determine the therapeutic antitumor effects and E7-specific CD8+ T cell immune response in TC-1 tumor-bearing mice treated with DMXAA combined with CRT/E7 DNA vaccination, we first challenged groups of C57BL/6 mice (5 per group) with TC-1 tumor cells and then treated them with CRT/E7 DNA vaccine with or without DMXAA as illustrated in Figure 2A.